(-0.01%) 5 478.00 points
(-0.04%) 38 804 points
(0.04%) 19 929 points
(0.27%) $80.55
(1.18%) $2.82
(0.19%) $2 333.40
(-0.29%) $29.31
(-0.14%) $969.50
(0.03%) $0.932
(-0.16%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Quarter results tomorrow
(tns 2024-06-19)
Expected move: +/- 10.16%
Live Chart Being Loaded With Signals
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...
Stats | |
---|---|
Šios dienos apimtis | 6.13M |
Vidutinė apimtis | 1.39M |
Rinkos kapitalizacija | 72.19M |
EPS | $-0.210 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.210 ) 2024-06-19 |
Last Dividend | $0.420 ( 2010-12-09 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.160 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00600 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Stergiou Angelos M. | Buy | 159 000 | Common Stock |
2024-01-22 | Stergiou Angelos M. | Buy | 238 500 | Stock Option (Right to Buy) |
2024-01-22 | Scheinberg David A | Buy | 6 000 | Common Stock |
2024-01-22 | Scheinberg David A | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-22 | Wood Barbara A | Buy | 35 000 | Common Stock |
INSIDER POWER |
---|
95.64 |
Last 98 transactions |
Buy: 3 194 450 | Sell: 76 679 |
Tūris Koreliacija
Sellas Life Sciences Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
CEG | 0.903 |
IINN | 0.899 |
VNOM | 0.893 |
FANG | 0.889 |
PWP | 0.884 |
APP | 0.883 |
MTEK | 0.881 |
BLIN | 0.878 |
WING | 0.877 |
EVBG | 0.877 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SOFO | -0.908 |
FXNC | -0.903 |
COMM | -0.896 |
WKME | -0.896 |
PDCO | -0.895 |
AIRS | -0.893 |
CNTG | -0.892 |
AKAN | -0.889 |
GMBLP | -0.888 |
SFST | -0.887 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sellas Life Sciences Koreliacija - Valiuta/Žaliavos
Sellas Life Sciences Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.340 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.340 |
FY | 2022 |
Pajamos: | $1.00M |
Bruto pelnas: | $900 000 (90.00 %) |
EPS: | $-2.10 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $-200 000 (0.00 %) |
EPS: | $-2.60 |
Financial Reports:
No articles found.
Sellas Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2010-09-09 |
Last Dividend | $0.420 | 2010-12-09 |
Next Dividend | $0 | N/A |
Payout Date | 2010-12-20 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.570 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.52 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.570 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
09 Dec 2010 | $0.420 | 30 Nov -0001 | 30 Nov -0001 | 20 Dec 2010 |
09 Sep 2010 | $0.150 | 07 Sep 2010 | 30 Nov -0001 | 22 Sep 2010 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.466 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -52.58 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.489 | 0.800 | 7.55 | 6.04 | [1 - 3] |
quickRatioTTM | 1.282 | 0.800 | 7.16 | 5.73 | [0.8 - 2.5] |
cashRatioTTM | 1.282 | 1.500 | 3.99 | 5.98 | [0.2 - 2] |
debtRatioTTM | 0.0328 | -1.500 | 9.45 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.670 | 2.00 | -0.223 | -0.447 | [0 - 30] |
freeCashFlowPerShareTTM | -0.860 | 2.00 | -0.430 | -0.860 | [0 - 20] |
debtEquityRatioTTM | 0.0827 | -1.500 | 9.67 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -37.51 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.367 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.777 | 1.000 | -0.281 | 0 | [1 - 100] |
returnOnEquityTTM | -52.58 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.860 | 2.00 | -0.287 | -0.860 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.670 | 2.00 | -0.223 | -0.447 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0519 | 1.500 | -2.99 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.828 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sellas Life Sciences
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.